Financial Performance - Fortive's revenue reached $4.1 billion, with a ~30% Adjusted EBITDA Margin[8] - The company generated $1.2 billion in Adjusted EBITDA[8] - Free cash flow amounted to $0.9 billion, exceeding 100% conversion on Adjusted Net Income[8] - Adjusted Gross Profit Margin stood at ~65%[8] - Core revenue growth from FY 2019 to FY 2024 was 4%, but only 2% in TTM Q3 2025[8, 9] Segment Performance - Intelligent Operating Solutions (IOS) reported $2.8 billion in revenue with a 35% Adjusted EBITDA Margin[8] - Advanced Healthcare Solutions (AHS) achieved $1.3 billion in revenue with a 27% Adjusted EBITDA Margin[8] Capital Allocation - Fortive deployed $1 billion in Q3 for share repurchases, representing approximately 21 million shares or 6% of fully diluted shares outstanding[12] Strategic Initiatives - The company completed the separation of its former Precision Technologies segment on June 28, 2025[4] - Fortive is focused on faster profitable organic growth powered by the Fortive Business System (FBS)[11]

Financial Data and Key Metrics Changes - In Q3, total revenue was just over $1 billion, reflecting a year-over-year increase of approximately 2% on both a reported and core basis [12][13] - Adjusted EBITDA grew by 10% year-over-year to $309 million, with an adjusted EBITDA margin expanding approximately 200 basis points to 30% [14][12] - Adjusted EPS increased by 15% year-over-year to $0.68, driven by growth in adjusted EBITDA and favorable interest expense [14][12] - Free cash flow for Q3 was $266 million, with trailing twelve-month free cash flow growing to $922 million [15][20] Business Line Data and Key Metrics Changes - Intelligent Operating Solutions (iOS) segment revenue grew just over 2.5% on a reported basis, with core revenue growth at 2% [15][16] - Advanced Healthcare Solutions (AHS) segment revenue was $328 million, growing approximately 2% year-over-year, with adjusted EBITDA margin expanding from roughly 27% to 28% [18][17] Market Data and Key Metrics Changes - North America showed solid growth, improving sequentially from Q2, driven by strengthening demand trends for professional instrumentation and healthcare equipment [13][12] - Europe experienced a year-over-year decline, worsened by weakening macro conditions [13] - The rest of the world showed mixed results, with significant acceleration in South Asia, particularly India [10][12] Company Strategy and Development Direction - The company is focused on driving profitable organic growth through the Fortive Business System, with a strategy centered on innovation acceleration, commercial acceleration, and recurring customer value [8][9] - Capital allocation priorities include investing in organic growth, pursuing accretive bolt-on M&A, returning capital through share repurchases, and maintaining a modest growing dividend [11][10] - The company is committed to maximizing medium to long-term shareholder returns through disciplined capital allocation [25][24] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the company's growth trajectory, emphasizing the benefits of simplification and a customer-centric approach [23][24] - The outlook for Q4 anticipates a moderation in overall core growth, with AHS core growth expected to be broadly in line with Q3 levels [21][22] - Management remains confident in the resilience of healthcare spending despite potential policy changes, citing strong customer loyalty and ongoing demand trends [104][105] Other Important Information - The company successfully completed the spin-off of its Precision Technologies segment, now operating independently as Rallian [3] - The company has revamped its M&A strategy to focus on smaller, bolt-on acquisitions rather than transformational M&A [41][42] Q&A Session Summary Question: Margin performance and Q4 guidance - Management acknowledged that Q3 margin performance was aided by cost discipline and discrete actions taken to free up resources for growth initiatives, with expectations for some reinvestment in Q4 [31][32] Question: Impact of government shutdown - Management indicated that the federal government shutdown has not significantly impacted their business, as their exposure is primarily to state and local agencies [34][35] Question: Capital allocation and buybacks - The company expressed satisfaction with the $1 billion share repurchase in Q3, reflecting strong free cash flow and attractive valuations, while emphasizing a balanced approach to capital allocation between buybacks and bolt-on M&A [40][41] Question: Demand trends in AHS - Management reported sequential improvement in demand for healthcare capital equipment in North America, driven by increased certainty around legislative conditions [58][59] Question: Software business performance - The software segment continues to perform well, with strong demand for facilities software and ongoing product innovation [66][67] Question: Simplification impact on growth - Management expects increasing impact from simplification efforts as they continue to free up resources for growth initiatives [75][76] Question: Regional demand trends - North America remains the strongest market, while Western Europe has been the softest, with mixed results in other regions [78][79]

Financial Data and Key Metrics Changes - In Q3, total revenue was just over $1 billion, reflecting a year-over-year increase of approximately 2% on both a reported and core basis [12][13] - Adjusted EBITDA was $309 million, up 10% year-over-year, with an adjusted EBITDA margin expanding approximately 200 basis points to 30% [14][15] - Adjusted EPS was $0.68, representing a 15% year-over-year increase, driven by growth in adjusted EBITDA and favorable interest expense [14][15] Business Line Data and Key Metrics Changes - **Intelligent Operating Solutions (iOS)**: Revenue grew just over 2.5% on a reported basis, with core revenue growth at 2%. Growth was driven by demand for facility and asset lifecycle software and professional instrumentation [15][16] - **Advanced Healthcare Solutions (AHS)**: Total revenue was $328 million, growing approximately 2% year-over-year. Demand trends improved sequentially, particularly for healthcare equipment and software [18][19] Market Data and Key Metrics Changes - North America showed solid growth, improving sequentially from Q2, driven by strengthening demand trends for professional instrumentation and healthcare equipment [13][18] - Europe experienced a decline year-over-year, worsened by weakening macro conditions [13] - The rest of the world showed mixed results, with significant acceleration in South Asia, particularly India [10][13] Company Strategy and Development Direction - The company is focused on driving profitable organic growth through its Fortive Business System, emphasizing innovation acceleration, commercial acceleration, and recurring customer value [8][10] - Capital allocation priorities include investing in organic growth, pursuing accretive bolt-on M&A, returning capital through share repurchases, and maintaining a modest growing dividend [11][19] - The company aims to simplify operations and enhance customer-centric approaches, which are expected to yield positive outcomes in the future [23][24] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the company's growth trajectory, citing strong customer relationships and a robust pipeline of growth opportunities [24][25] - The company anticipates a moderation in overall core growth in Q4, with AHS core growth expected to align with Q3 levels [21][22] - Management remains confident in the healthcare market's resilience despite potential policy changes, driven by aging demographics and increasing healthcare needs [105][106] Other Important Information - The company successfully completed the spin-off of its Precision Technologies segment, now operating as Rallian, on June 28, 2025 [3][4] - The company deployed $1 billion for share repurchases in Q3, retiring approximately 21 million shares, reflecting confidence in its value creation plan [7][19] Q&A Session Summary Question: Margin performance and Q4 guidance - Management acknowledged that Q3 margin performance was aided by cost discipline and discrete actions taken to free up resources for growth initiatives, with expectations to maintain cost discipline in Q4 [31][32] Question: Impact of government shutdown - Management indicated that the federal government shutdown has minimal direct exposure for the company, primarily affecting state and local government agencies [34][35] Question: Capital allocation and M&A strategy - Management confirmed that share repurchases will be a significant part of capital allocation, focusing on smaller bolt-on acquisitions rather than transformational M&A [40][42] Question: Fluke performance and demand indicators - Management reported strong order growth and stable sell-through patterns for Fluke, with improvements in channel inventory and ongoing product innovation [43][44] Question: AHS segment demand trends - Management noted sequential improvement in demand for healthcare capital equipment and consumables, driven by more certainty in legislative conditions [56][58] Question: Tax rate outlook - Management projected a mid-teens effective tax rate for the next few years, with potential risks from new proposals [59][60] Question: Software business performance - Management highlighted strong growth in the software segment, particularly in AI-related applications, and noted that IT spending remains robust [66][68] Question: Demand trends by region - Management indicated strong performance in North America, while Western Europe remains soft, with mixed results in other regions [78][79]

Financial Data and Key Metrics Changes - In Q3 2025, total revenue was just over $1 billion, reflecting a year-over-year increase of approximately 2% on both a reported and core basis [11] - Adjusted EBITDA grew by 10% year-over-year to $309 million, with an adjusted EBITDA margin expanding by approximately 200 basis points to 30% [12] - Adjusted EPS was $0.68, up 15% year-over-year, driven by growth in adjusted EBITDA and favorable interest expense on lower debt balances [12][19] Business Line Data and Key Metrics Changes - Intelligent Operating Solutions (iOS) segment revenue grew just over 2.5% on a reported basis, with core revenue growth at 2% [14] - Advanced Healthcare Solutions (AHS) segment revenue was $328 million, growing approximately 2% year-over-year, with adjusted EBITDA margin expanding from roughly 27% to 28% [17] Market Data and Key Metrics Changes - North America showed solid growth, improving sequentially from Q2, driven by strengthening demand trends for professional instrumentation and healthcare equipment [11] - Europe experienced a year-over-year decline, worsened modestly from Q2 due to weakening macro conditions [11] - The rest of the world showed mixed results, with significant acceleration in South Asia, particularly India, which is expected to drive strong momentum in the coming years [9] Company Strategy and Development Direction - The company is focused on driving profitable organic growth through its Fortive Business System, with a strategy centered on innovation acceleration, commercial acceleration, and recurring customer value [6][24] - Capital allocation priorities include investing in organic growth, pursuing accretive bolt-on M&A, returning capital through share repurchases, and maintaining a modest growing dividend [10][39] - The company is committed to maximizing medium to long-term shareholder returns and has demonstrated this through significant share repurchases [5][18] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the company's growth trajectory, emphasizing the importance of customer-centric operations and the simplification of the organizational model [22][23] - The company expects overall core growth to moderate in Q4, with AHS core growth broadly in line with Q3 levels and very modest core growth at iOS [19][95] - Management remains confident in the healthcare market's resilience, citing aging demographics and increasing healthcare needs as long-term growth drivers [97] Other Important Information - The company successfully completed the spin-off of its Precision Technologies segment, now operating independently as Rallian, on June 28, 2025 [2] - Free cash flow for Q3 was $266 million, with trailing twelve-month free cash flow growing to $922 million [13][18] Q&A Session Summary Question: Margin performance and Q4 guidance - Management noted that Q3 margin performance was driven by revenue performance and cost discipline, with expectations to maintain cost discipline while reinvesting some resources in Q4 [31][32] Question: Impact of government shutdown on performance - The company indicated that its exposure to federal government funding is minimal, and the shutdown has not significantly impacted performance [34] Question: Capital allocation and buyback strategy - Management explained that the $1 billion share repurchase was based on strong free cash flow and attractive valuations, with a focus on smaller bolt-on acquisitions for growth [38][39] Question: Demand trends in AHS segment - Management reported sequential improvement in demand for healthcare capital equipment and consumables, driven by more certainty in legislative conditions [52] Question: Tax rate outlook - The CFO indicated that a mid-teens tax rate is a good framework for modeling through 2026, with potential risks from new proposals [53] Question: Demand by region - North America continues to perform strongly, while Western Europe remains soft, with mixed results in other regions [69]

Financial Data and Key Metrics Changes - The company delivered total revenue of just over $1 billion, down 0.4% year over year, with core revenue declining 0.7% [18][20] - Adjusted EPS was $0.58, up 4% year over year, driven by stable adjusted EBITDA and lower interest expenses [20][21] - Free cash flow for Q2 was $180 million, with trailing twelve-month free cash flow of $939 million, representing a 14% year-over-year increase [21][30] Business Line Data and Key Metrics Changes - Intelligent Operating Solutions segment saw revenue and core revenue growth essentially flat year over year, with adjusted gross profit at $461 million, down slightly from the prior year [22][24] - Advanced Healthcare Solutions segment delivered total revenue of $320 million, down 1.3% year over year, with adjusted gross margins increasing from just under 58% to just over 59% [26][28] Market Data and Key Metrics Changes - North America showed slight positive growth, while Western Europe, China, and Latin America experienced year-over-year declines [19][20] - The company noted that customer demand pressures were influenced by macroeconomic factors, including tariff uncertainty and constrained government spending [7][19] Company Strategy and Development Direction - The company is focused on executing its Fortive Accelerated strategy, which includes innovation acceleration, commercial acceleration, and enhancing recurring customer value [11][12] - The company is initiating guidance for continuing operations, reflecting a full-year outlook consistent with its new approach of providing clear and simplified guidance [8][32] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to navigate macro pressures and emphasized the importance of the projects in the pipeline for government spending [50][51] - The company anticipates that the revenue slip experienced in Q2 will normalize in the coming quarters, with a strong outlook for the second half of the year [22][55] Other Important Information - The company received a $1.15 billion dividend from the Rallyant spinoff, which was used to pay down debt and fund share repurchases [30][31] - The gross tariff impact for Fortive's continuing operations is expected to be approximately $40 million to $55 million in 2025, with annualized impacts of $80 million to $120 million [29] Q&A Session Summary Question: Insights on second half moving pieces between Q3 and Q4 - Management confirmed that Q3 EPS is expected to be in the low to mid-50s range, with a sequential increase in Q4 driven by tax rate drops and tariff countermeasures [42][44] Question: Government spending and healthcare market outlook - Management noted that while government spending pressures exist, essential projects are still in the pipeline, and healthcare spending is expected to recover as reimbursement policies stabilize [50][51] Question: Clarification on organic sales growth expectations - Management indicated that organic sales growth in Q3 is expected to be consistent with the modest decline seen in Q2, with AHS facing high year-over-year comps [60][64] Question: Renewal rates for Gordian or iOS software - Management reported strong renewal rates across all software businesses, with a focus on expanding and cross-selling to enhance net dollar retention [67][68] Question: Rationale behind not providing high-level organic growth guidance - Management emphasized the intention to simplify communications with investors while maintaining focus on a multi-year value creation plan [73][74] Question: Approach to bolt-on acquisitions - Management clarified that there is a heightened level of scrutiny for bolt-on acquisitions, with a focus on ensuring that each deal meets high strategic and financial criteria [78][79]

Core Insights - Fluke Corporation has appointed Parker Burke as President and Group President of Fortive's Connected Reliability Group effective July 7, 2025, to enhance technology and services aimed at reducing downtime and increasing operational resilience [1][4]. Company Overview - Fluke Corporation, founded in 1948, is a leader in compact, professional electronic test tools and software for measuring and condition monitoring, serving technicians, engineers, electricians, and maintenance managers [7]. - Fluke is a wholly owned subsidiary of Fortive Corporation, which was formed in 2016 after Danaher spun off several businesses [8]. Leadership Background - Parker Burke has 15 years of leadership experience within Fortive, previously serving as Group President of Fortive's Environmental Health & Safety Group, where he advanced innovation in connected safety and environmental health software [2][4]. - Burke is recognized for embedding the Fortive Business System across teams and fostering a culture of continuous improvement, with prior leadership roles at Gilbarco Veeder-Root and Anderson-Negele [5]. Strategic Focus - Under Burke's leadership, Fluke aims to scale AI-driven solutions, precision measurement, and connected workflows to transition customers from reactive to predictive operations [4]. - Burke emphasizes the importance of Fluke's heritage of precision, safety, and innovation in addressing critical challenges faced by the industrial workforce [6].

New Fortive Overview - New Fortive is a simplified company with a track record of strong financial performance, supported by approximately 50% recurring revenues[14, 29] - The company is strategically positioned in attractive markets with a clear path to accelerate value creation[14, 29] - New Fortive's revenue is \$41 billion, with Intelligent Operating Solutions (IOS) contributing approximately \$28 billion (approximately 70%) and Advanced Healthcare Solutions (AHS) contributing approximately \$13 billion (approximately 30%)[23] - The company has a higher quality financial profile with 4% core revenue growth, approximately 50% recurring revenue, 64% adjusted gross margin, 10% adjusted EBITDA growth, and 17% FCF growth[24] Business Segments and Market Opportunities - Intelligent Operating Solutions (IOS) has a \$35 billion addressable market with low to mid-single-digit market growth outlook[36, 41] - Advanced Healthcare Solutions (AHS) has a \$10 billion addressable market with low to mid-single-digit market growth outlook[36, 42] - Fluke's addressable market has expanded from \$7 billion to \$15 billion, with double-digit market growth in areas like solar and EV charging[154, 155] - Facility and Asset Lifecycle (FAL) Software has an \$11 billion addressable market with mid-single-digit market growth[191] Financial Performance and Projections - New Fortive has demonstrated strong historical performance, including 4% core growth CAGR, 9% adjusted gross profit CAGR, 12% adjusted EBITDA CAGR, and 12% FCF CAGR[27] - The company projects 3-4% core revenue CAGR for the next few years (2026-2027) and beyond (2028 onwards)[78, 225] - Adjusted EBITDA margin is expected to expand by approximately 50-100 bps annually on average[78, 225] - Adjusted EPS growth is projected to be in the high single digits plus CAGR at a constant tax rate[78, 225]